{
  "success": true,
  "pagesUsed": [
    1,
    2,
    3,
    4,
    5,
    6,
    8,
    9,
    10,
    11,
    18,
    19,
    20,
    21,
    22,
    23,
    24,
    25,
    26,
    27,
    28,
    29
  ],
  "modelUsed": "gemini-3-flash-preview",
  "objectivesEndpoints": {
    "objectives": [
      {
        "id": "obj_1",
        "name": "Primary Efficacy Objective",
        "text": "In subjects with T2DM, Stage 2 or 3 CKD and macroalbuminuria who are receiving standard of care, to assess the efficacy of canagliflozin relative to placebo in reducing: The composite endpoint of end-stage kidney disease (ESKD), doubling of serum creatinine, and renal or cardiovascular (CV) death",
        "level": {
          "code": "C85826",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Primary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_1"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_2",
        "name": "Secondary Efficacy Objective 1",
        "text": "To assess the efficacy of canagliflozin relative to placebo in reducing: The composite endpoint of CV death and hospitalized congestive heart failure",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_2"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_3",
        "name": "Secondary Efficacy Objective 2",
        "text": "To assess the efficacy of canagliflozin relative to placebo in reducing: The composite endpoint of CV death, non-fatal myocardial infarction (MI), and non-fatal stroke (ie, 3-point major adverse cardiac event [MACE])",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_3"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_4",
        "name": "Secondary Efficacy Objective 3",
        "text": "To assess the efficacy of canagliflozin relative to placebo in reducing: Hospitalized congestive heart failure",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_4"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_5",
        "name": "Secondary Efficacy Objective 4",
        "text": "To assess the efficacy of canagliflozin relative to placebo in reducing: The renal composite endpoint of ESKD, doubling of serum creatinine, and renal death",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_5"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_6",
        "name": "Secondary Efficacy Objective 5",
        "text": "To assess the efficacy of canagliflozin relative to placebo in reducing: CV death",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_6"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_7",
        "name": "Secondary Efficacy Objective 6",
        "text": "To assess the efficacy of canagliflozin relative to placebo in reducing: All-cause death",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_7"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_8",
        "name": "Secondary Efficacy Objective 7",
        "text": "To assess the efficacy of canagliflozin relative to placebo in reducing: The CV composite endpoint of CV death, non-fatal MI, non-fatal stroke, hospitalized congestive heart failure, and hospitalized unstable angina",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_8"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_9",
        "name": "Exploratory Objective 1",
        "text": "To assess the efficacy of canagliflozin relative to placebo in reducing: The composite endpoint of ESKD and renal or CV death",
        "level": {
          "code": "C163559",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Exploratory Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_9"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_10",
        "name": "Exploratory Objective 2",
        "text": "To assess the impact of canagliflozin relative to placebo on: Changes in estimated glomerular filtration rate (eGFR) over time",
        "level": {
          "code": "C163559",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Exploratory Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_10"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_11",
        "name": "Exploratory Objective 3",
        "text": "To assess the impact of canagliflozin relative to placebo on: Changes in albuminuria over time",
        "level": {
          "code": "C163559",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Exploratory Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_11"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_12",
        "name": "Safety Objective",
        "text": "To assess the overall safety and tolerability of canagliflozin.",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_12"
        ],
        "instanceType": "Objective"
      }
    ],
    "endpoints": [
      {
        "id": "ep_1",
        "name": "Primary Efficacy Outcome",
        "text": "The first occurrence of ESKD, doubling of serum creatinine, and renal or CV death.",
        "level": {
          "code": "C98772",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Primary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_2",
        "name": "Secondary Efficacy Outcome 1",
        "text": "The composite endpoint of CV death and hospitalized congestive heart failure",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_3",
        "name": "Secondary Efficacy Outcome 2",
        "text": "The composite endpoint of CV death, non-fatal MI, and non-fatal stroke (ie, 3-point MACE)",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_4",
        "name": "Secondary Efficacy Outcome 3",
        "text": "Hospitalized congestive heart failure",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_5",
        "name": "Secondary Efficacy Outcome 4",
        "text": "The renal composite endpoint of ESKD, doubling of serum creatinine and renal death",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_6",
        "name": "Secondary Efficacy Outcome 5",
        "text": "CV death",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_7",
        "name": "Secondary Efficacy Outcome 6",
        "text": "All-cause death",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_8",
        "name": "Secondary Efficacy Outcome 7",
        "text": "The CV composite endpoint of CV death, non-fatal MI, non-fatal stroke, hospitalized congestive heart failure, and hospitalized unstable angina",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_9",
        "name": "Exploratory Efficacy Outcome 1",
        "text": "Reduction in the composite endpoint of ESKD and renal or CV death",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_10",
        "name": "Exploratory Efficacy Outcome 2",
        "text": "Changes in eGFR over time",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_11",
        "name": "Exploratory Efficacy Outcome 3",
        "text": "Changes in albuminuria over time",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_12",
        "name": "Safety Outcomes",
        "text": "The overall safety and tolerability of canagliflozin. The safety evaluations include the collection of adverse events, laboratory tests, vital signs (pulse, blood pressure), physical examination, and body weight.",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      }
    ],
    "estimands": [
      {
        "id": "est_1",
        "name": "Primary Efficacy Estimand",
        "populationSummary": "Adults (≥30 years) with T2DM, Stage 2 or 3 CKD (eGFR 30 to <90 mL/min/1.73m2), and macroalbuminuria (UACR >300 to ≤5000 mg/g) on stable ACEi or ARB therapy. Summary measure: Hazard ratio.",
        "analysisPopulationId": "est_1_pop",
        "variableOfInterestId": "ep_1",
        "interventionIds": [
          "est_1_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_1",
            "name": "Treatment discontinuation",
            "text": "Premature discontinuation of study drug for any reason",
            "strategy": "Treatment Policy",
            "instanceType": "IntercurrentEvent"
          },
          {
            "id": "ice_2",
            "name": "Death",
            "text": "Death due to non-renal and non-CV causes",
            "strategy": "Composite",
            "instanceType": "IntercurrentEvent"
          },
          {
            "id": "ice_3",
            "name": "Initiation of rescue medication",
            "text": "Use of additional antihyperglycemic or antihypertensive therapies to reach clinical goals",
            "strategy": "Treatment Policy",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "Canagliflozin 100 mg daily vs Placebo",
        "analysisPopulation": "Adults (≥30 years) with T2DM, Stage 2 or 3 CKD (eGFR 30 to <90 mL/min/1.73m2), and macroalbuminuria (UACR >300 to ≤5000 mg/g) on stable ACEi or ARB therapy.",
        "variableOfInterest": "Time from randomization to the first occurrence of ESKD, doubling of serum creatinine, and renal or CV death",
        "summaryMeasure": "Hazard ratio"
      },
      {
        "id": "est_2",
        "name": "Secondary Efficacy Estimand - MACE",
        "populationSummary": "Adults (≥30 years) with T2DM, Stage 2 or 3 CKD (eGFR 30 to <90 mL/min/1.73m2), and macroalbuminuria (UACR >300 to ≤5000 mg/g) on stable ACEi or ARB therapy. Summary measure: Hazard ratio.",
        "analysisPopulationId": "est_2_pop",
        "variableOfInterestId": "ep_3",
        "interventionIds": [
          "est_2_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_1",
            "name": "Treatment discontinuation",
            "text": "Premature discontinuation of study drug for any reason",
            "strategy": "Treatment Policy",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "Canagliflozin 100 mg daily vs Placebo",
        "analysisPopulation": "Adults (≥30 years) with T2DM, Stage 2 or 3 CKD (eGFR 30 to <90 mL/min/1.73m2), and macroalbuminuria (UACR >300 to ≤5000 mg/g) on stable ACEi or ARB therapy.",
        "variableOfInterest": "Time from randomization to the first occurrence of CV death, non-fatal MI, and non-fatal stroke",
        "summaryMeasure": "Hazard ratio"
      },
      {
        "id": "est_3",
        "name": "Exploratory Efficacy Estimand - eGFR Slope",
        "populationSummary": "Adults (≥30 years) with T2DM, Stage 2 or 3 CKD (eGFR 30 to <90 mL/min/1.73m2), and macroalbuminuria (UACR >300 to ≤5000 mg/g) on stable ACEi or ARB therapy. Summary measure: Slope difference (coefficient for treatment and time interaction).",
        "analysisPopulationId": "est_3_pop",
        "variableOfInterestId": "ep_10",
        "interventionIds": [
          "est_3_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_4",
            "name": "Treatment discontinuation",
            "text": "Discontinuation of study drug",
            "strategy": "While on Treatment",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "Canagliflozin 100 mg daily vs Placebo",
        "analysisPopulation": "Adults (≥30 years) with T2DM, Stage 2 or 3 CKD (eGFR 30 to <90 mL/min/1.73m2), and macroalbuminuria (UACR >300 to ≤5000 mg/g) on stable ACEi or ARB therapy.",
        "variableOfInterest": "Changes in eGFR over time",
        "summaryMeasure": "Slope difference (coefficient for treatment and time interaction)"
      }
    ],
    "summary": {
      "primaryObjectives": 1,
      "secondaryObjectives": 8,
      "exploratoryObjectives": 3,
      "totalEndpoints": 12,
      "totalEstimands": 3
    }
  },
  "rawResponse": {
    "objectives": [
      {
        "id": "obj_1",
        "name": "Primary Efficacy Objective",
        "text": "In subjects with T2DM, Stage 2 or 3 CKD and macroalbuminuria who are receiving standard of care, to assess the efficacy of canagliflozin relative to placebo in reducing: The composite endpoint of end-stage kidney disease (ESKD), doubling of serum creatinine, and renal or cardiovascular (CV) death",
        "level": {
          "code": "C85826",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Primary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_1"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_2",
        "name": "Secondary Efficacy Objective 1",
        "text": "To assess the efficacy of canagliflozin relative to placebo in reducing: The composite endpoint of CV death and hospitalized congestive heart failure",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_2"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_3",
        "name": "Secondary Efficacy Objective 2",
        "text": "To assess the efficacy of canagliflozin relative to placebo in reducing: The composite endpoint of CV death, non-fatal myocardial infarction (MI), and non-fatal stroke (ie, 3-point major adverse cardiac event [MACE])",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_3"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_4",
        "name": "Secondary Efficacy Objective 3",
        "text": "To assess the efficacy of canagliflozin relative to placebo in reducing: Hospitalized congestive heart failure",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_4"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_5",
        "name": "Secondary Efficacy Objective 4",
        "text": "To assess the efficacy of canagliflozin relative to placebo in reducing: The renal composite endpoint of ESKD, doubling of serum creatinine, and renal death",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_5"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_6",
        "name": "Secondary Efficacy Objective 5",
        "text": "To assess the efficacy of canagliflozin relative to placebo in reducing: CV death",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_6"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_7",
        "name": "Secondary Efficacy Objective 6",
        "text": "To assess the efficacy of canagliflozin relative to placebo in reducing: All-cause death",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_7"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_8",
        "name": "Secondary Efficacy Objective 7",
        "text": "To assess the efficacy of canagliflozin relative to placebo in reducing: The CV composite endpoint of CV death, non-fatal MI, non-fatal stroke, hospitalized congestive heart failure, and hospitalized unstable angina",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_8"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_9",
        "name": "Exploratory Objective 1",
        "text": "To assess the efficacy of canagliflozin relative to placebo in reducing: The composite endpoint of ESKD and renal or CV death",
        "level": {
          "code": "C163559",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Exploratory Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_9"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_10",
        "name": "Exploratory Objective 2",
        "text": "To assess the impact of canagliflozin relative to placebo on: Changes in estimated glomerular filtration rate (eGFR) over time",
        "level": {
          "code": "C163559",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Exploratory Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_10"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_11",
        "name": "Exploratory Objective 3",
        "text": "To assess the impact of canagliflozin relative to placebo on: Changes in albuminuria over time",
        "level": {
          "code": "C163559",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Exploratory Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_11"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_12",
        "name": "Safety Objective",
        "text": "To assess the overall safety and tolerability of canagliflozin.",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_12"
        ],
        "instanceType": "Objective"
      }
    ],
    "endpoints": [
      {
        "id": "ep_1",
        "name": "Primary Efficacy Outcome",
        "text": "The first occurrence of ESKD, doubling of serum creatinine, and renal or CV death.",
        "level": {
          "code": "C98772",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Primary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_2",
        "name": "Secondary Efficacy Outcome 1",
        "text": "The composite endpoint of CV death and hospitalized congestive heart failure",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_3",
        "name": "Secondary Efficacy Outcome 2",
        "text": "The composite endpoint of CV death, non-fatal MI, and non-fatal stroke (ie, 3-point MACE)",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_4",
        "name": "Secondary Efficacy Outcome 3",
        "text": "Hospitalized congestive heart failure",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_5",
        "name": "Secondary Efficacy Outcome 4",
        "text": "The renal composite endpoint of ESKD, doubling of serum creatinine and renal death",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_6",
        "name": "Secondary Efficacy Outcome 5",
        "text": "CV death",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_7",
        "name": "Secondary Efficacy Outcome 6",
        "text": "All-cause death",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_8",
        "name": "Secondary Efficacy Outcome 7",
        "text": "The CV composite endpoint of CV death, non-fatal MI, non-fatal stroke, hospitalized congestive heart failure, and hospitalized unstable angina",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_9",
        "name": "Exploratory Efficacy Outcome 1",
        "text": "Reduction in the composite endpoint of ESKD and renal or CV death",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_10",
        "name": "Exploratory Efficacy Outcome 2",
        "text": "Changes in eGFR over time",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_11",
        "name": "Exploratory Efficacy Outcome 3",
        "text": "Changes in albuminuria over time",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_12",
        "name": "Safety Outcomes",
        "text": "The overall safety and tolerability of canagliflozin. The safety evaluations include the collection of adverse events, laboratory tests, vital signs (pulse, blood pressure), physical examination, and body weight.",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      }
    ],
    "estimands": [
      {
        "id": "est_1",
        "name": "Primary Efficacy Estimand",
        "populationSummary": "Adults (≥30 years) with T2DM, Stage 2 or 3 CKD (eGFR 30 to <90 mL/min/1.73m2), and macroalbuminuria (UACR >300 to ≤5000 mg/g) on stable ACEi or ARB therapy. Summary measure: Hazard ratio.",
        "analysisPopulationId": "est_1_pop",
        "variableOfInterestId": "ep_1",
        "interventionIds": [
          "est_1_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_1",
            "name": "Treatment discontinuation",
            "text": "Premature discontinuation of study drug for any reason",
            "strategy": "Treatment Policy",
            "instanceType": "IntercurrentEvent"
          },
          {
            "id": "ice_2",
            "name": "Death",
            "text": "Death due to non-renal and non-CV causes",
            "strategy": "Composite",
            "instanceType": "IntercurrentEvent"
          },
          {
            "id": "ice_3",
            "name": "Initiation of rescue medication",
            "text": "Use of additional antihyperglycemic or antihypertensive therapies to reach clinical goals",
            "strategy": "Treatment Policy",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "Canagliflozin 100 mg daily vs Placebo",
        "analysisPopulation": "Adults (≥30 years) with T2DM, Stage 2 or 3 CKD (eGFR 30 to <90 mL/min/1.73m2), and macroalbuminuria (UACR >300 to ≤5000 mg/g) on stable ACEi or ARB therapy.",
        "variableOfInterest": "Time from randomization to the first occurrence of ESKD, doubling of serum creatinine, and renal or CV death",
        "summaryMeasure": "Hazard ratio"
      },
      {
        "id": "est_2",
        "name": "Secondary Efficacy Estimand - MACE",
        "populationSummary": "Adults (≥30 years) with T2DM, Stage 2 or 3 CKD (eGFR 30 to <90 mL/min/1.73m2), and macroalbuminuria (UACR >300 to ≤5000 mg/g) on stable ACEi or ARB therapy. Summary measure: Hazard ratio.",
        "analysisPopulationId": "est_2_pop",
        "variableOfInterestId": "ep_3",
        "interventionIds": [
          "est_2_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_1",
            "name": "Treatment discontinuation",
            "text": "Premature discontinuation of study drug for any reason",
            "strategy": "Treatment Policy",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "Canagliflozin 100 mg daily vs Placebo",
        "analysisPopulation": "Adults (≥30 years) with T2DM, Stage 2 or 3 CKD (eGFR 30 to <90 mL/min/1.73m2), and macroalbuminuria (UACR >300 to ≤5000 mg/g) on stable ACEi or ARB therapy.",
        "variableOfInterest": "Time from randomization to the first occurrence of CV death, non-fatal MI, and non-fatal stroke",
        "summaryMeasure": "Hazard ratio"
      },
      {
        "id": "est_3",
        "name": "Exploratory Efficacy Estimand - eGFR Slope",
        "populationSummary": "Adults (≥30 years) with T2DM, Stage 2 or 3 CKD (eGFR 30 to <90 mL/min/1.73m2), and macroalbuminuria (UACR >300 to ≤5000 mg/g) on stable ACEi or ARB therapy. Summary measure: Slope difference (coefficient for treatment and time interaction).",
        "analysisPopulationId": "est_3_pop",
        "variableOfInterestId": "ep_10",
        "interventionIds": [
          "est_3_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_4",
            "name": "Treatment discontinuation",
            "text": "Discontinuation of study drug",
            "strategy": "While on Treatment",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "Canagliflozin 100 mg daily vs Placebo",
        "analysisPopulation": "Adults (≥30 years) with T2DM, Stage 2 or 3 CKD (eGFR 30 to <90 mL/min/1.73m2), and macroalbuminuria (UACR >300 to ≤5000 mg/g) on stable ACEi or ARB therapy.",
        "variableOfInterest": "Changes in eGFR over time",
        "summaryMeasure": "Slope difference (coefficient for treatment and time interaction)"
      }
    ]
  }
}